|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 慢性丙型肝炎合并脂肪肝的发病机制显示文摘慢性丙型肝炎(CHC)合并脂肪肝是CHC患者的主要临床表现,脂肪肝对CHC患者病情发展及其抗病毒疗效都有重要影响,归纳了近年来CHC患者并发脂肪肝的病毒和宿主方面的因素及脂肪肝对CHC患者预后的影响。CHC合并脂肪肝的发生机制仍然有待于进一步深入研究。 | 魏芳芳 张晓红 | 2015 | 临床肝胆病杂志2015，31，2： | 5 |
| 2 | IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C显示文摘AIM:To evaluate the effect of single nucleotide polymorphisms of interleukin(IL)-28B,rs12979860 on progression and treatment response in chronic hepatitis C.METHODS:Patients(n = 64;37 men,27 women;mean age,44 ± 12 years) with chronic hepatitis C,genotype 1,received treatment with peg-interferon plus ribavirin.Genotyping of rs12979860 was performed on peripheral blood DNA.Histopathological assessment of necroinflammatory grade and fibrosis stage were scored using the METAVIR system on a liver biopsy sample before treatment.Serum viral load,aminotransferase activity,and insulin level were measured.Insulin resistance index,body mass index,waist/hip ratio,percentage of body fat and fibrosis progression rate were calculated.Applied dose of interferon and ribavirin,platelet and neutrophil count and hemoglobin level were measured.RESULTS:A sustained virological response(SVR) was significantly associated with IL28B polymorphism(CC vs TT allele:odds ratio(OR),25;CC vs CT allele:OR,5.4),inflammation activity(G < 1 vs G > 1:OR,3.9),fibrosis(F < 1 vs F > 1:OR,5.9),platelet count(> 200 × 10 9 /L vs < 200 × 10 9 /L:OR,4.7;OR in patients with genotype CT:12.8),fatty liver(absence vs presence of steatosis:OR,4.8),insulin resistance index(< 2.5 vs > 2.5:OR,3.9),and baseline HCV viral load(< 10 6 IU/mL vs > 10 6 IU/mL:OR,3.0).There was no association with age,sex,aminotransferases activity,body mass index,waist/hip ratio,or percentage body fat.There was borderline significance(P = 0.064) of increased fibrosis in patients with the TT allele,and no differences in the insulin resistance index between groups of patients with CC,CT and TT alleles(P = 0.12).Spearman's rank correlation coefficient between insulin resistance and stage of fibrosis and body mass index was r = 0.618 and r = 0.605,respectively(P < 0.001).Significant differences were found in the insulin resistance index(P = 0.01) between patients with and without steatosis.Patients with the CT allele and absence of a SVR had a higher incidence of requiring threshold dose reduction of interferon(P = 0.07).CONCLUSION:IL28B variation is the strongest host factor not related to insulin resistance that determines outcome of antiviral therapy.Baseline platelet count predicts the outcome of antiviral therapy in CT allele patients. | Andrzej Ciela Monika Bociaga-Jasik Iwona Sobczyk-Krupiarz Mikolaj K Glowacki Danuta Owczarek Dorota Cibor Marek Sanak Tomasz Mach | 2012 | World Journal of Gastroenterology2012，18，35： | 4 |
| 3 | 出入境人员丙型肝炎病毒感染者miRNA-122表达变化研究显示文摘目的探讨珠海口岸出入境人员丙型肝炎病毒(HCV RNA)感染者外周血miRNA-122表达的变化及其对丙型肝炎患者的临床意义。方法收集96例丙型肝炎IgG抗体初筛阳性患者外周血,定量检测HCV RNA水平。对HCV RNA阳性患者检测miRNA-122、丙氨酸氨基转移酶(ALT)及检查肝脏超声影像学改变,并进行相关性分析。结果 96例HCV IgG阳性患者检测出49例HCV RNA阳性,占60.9%;两组患者miRNA-122表达水平差异有统计学意义(P<0.01);与ALT呈正相关,与HCV RNA无相关性。B超检查发现11例合并轻度脂肪肝,合并脂肪肝患者miRNA-122表达水平高于无脂肪肝患者。结论 HCV阳性患者循环miRNA-122表达可能与病毒复制无关,而是反映肝脏组织活动性损害和病变严重性的指标。 | 史咏梅 冯子力 伍碧梅 唐明慧 王琪 涂承宁 谭华 叶立青 | 2016 | 检验医学与临床2016，13，6： | 3 |
| 4 | 二甲双胍对糖尿病合并乙型肝炎患者的影响显示文摘目的探讨二甲双胍对2型糖尿病合并乙型病毒性肝炎(简称乙肝)患者病毒复制和肝功能的影响。方法将82例有乙肝病史的新诊断2型糖尿病患者随机分为二甲双胍组(40例)和非二甲双胍治疗组(42例)进行降血糖治疗;在开始降血糖治疗前和治疗3个月后检测患者血压、身高、体重、腰围、肝功能、血脂、血糖、胰岛素、乙肝DNA、乙肝血清学等一般临床资料和生化指标并进行分析比较。结果二甲双胍组和非二甲双胍组均可明显改善患者血糖和B细胞功能(P〈0.05)。二甲双胍组在改善腰围、甘油三酯、BMI和胰岛素敏感指数方面优于非二甲双胍组(P〈0.05)。同时二甲双胍对肝功能和乙肝病毒复制无明显作用,与非二甲双胍组差异尢统计学意义。结论二甲双胍用于无严重并发症的2型糖尿病合并乙肝患者较为安全有效。 | 高凌 叶惠凤 | 2015 | 临床内科杂志2015，32，11： | 2 |
| 5 | 脂肪肝患者腹部手术风险及一级亲属癌症的发病率研究显示文摘目的探讨脂肪肝患者进行腹部手术的风险,以及患者一级亲属癌症的发病率。方法对70例非酒精性脂肪肝(nonalcoholic fatty liver disease,NAFLD)患者,80例已被证实的丙型肝炎患者(其中40例脂肪肝,40例为非脂肪肝),35例炎症性肠病(inflammatory bowel disease,IBD)患者及70例消化不良患者进行评估。结果各个分组中,患者的性别、年龄及婚姻状况差异无统计学意义(P>0.05)(除IBD患者的年龄较其他各组偏小)。其中IBD患者亲属癌症发病率为19.2%,消化不良发病率为10.8%,伴随脂肪变性的C型肝炎发病率为30.7%,无脂肪变性的C型肝炎发病率为21.0%,NAFLD的发病率为28.8%。随后将各研究组重新分为两组:无脂肪性肝病患者(IBD、消化不良、无脂肪变性的C型肝炎)和脂肪性肝病患者(伴随脂肪变性的C型肝炎、NAFLD)。无脂肪性肝病患者癌症发生率为17%,明显低于脂肪性肝病患者(26.7%,P<0.05)。同时调查了脂肪肝患者腹部手术的风险,结果无脂肪性肝病患者手术发生率为32.0%,低于脂肪性肝病(45.0%,P<0.05)。结论脂肪性肝病可以增加脂肪肝患者腹部手术的风险及一级亲属癌症的发病率。因此阐明脂肪性肝病的潜在原因可以减少癌症的发病率及脂肪肝患者手术的数量。 | 王志勇 邓国孙 | 2016 | 胃肠病学和肝病学杂志2016，25，3： | 2 |
| 6 | Retrospective study of the associations between hepatitis C virus infection and metabolic factors显示文摘AIM To evaluate the bidirectional association between metabolic syndrome(MS) components and antiviral treatment response for chronic hepatitis C virus(HCV) infection. METHODS This retrospective cohort study included 119 HCV + patients treated with pegylated-interferon-α and ribavirin. Metabolic characteristics and laboratory data were collected from medical records. Differences in baseline clinical and demographic risk factors between responders and non-responders were assessed using independent samples t-tests or χ~2 tests. The effects of sustained viral response(SVR) to antiviral treatment on de novo impairments in MS components, including impaired fasting glucose(IFG) and type 2 diabetes mellitus(T2DM), were assessed using univariable and multivariable logistic regression analysis, while the effect of MS components on SVR was assessed using univariable logistic regression analysis. RESULTS Of the 119 patients, 80(67%) developed SVR over the average 54 ± 13 mo follow-up. The cumulative risks for de novo T2DM and IFG were 5.07-(95%CI: 1.261-20.4, P = 0.022) and 3.87-fold higher(95%CI: 1.484-10.15, P = 0.006), respectively for non-responders than responders, when adjusted for the baseline risk factors age, sex, HCV genotype, high viral load, and steatosis. Post-treatment triglyceride levels were significantly lower in non-responders than in responders(OR = 0.27; 95%CI: 0.069-0.962, P = 0.044). Age and HCV genotype 3 were significantly different between responders and non-responders, and MS components were not significantly associated with SVR. Steatosis tended to attenuate SVR(OR = 0.596; 95%CI: 0.331-1.073, P = 0.08).CONCLUSION SVR was associated with lower de novo T2DM and IFG incidence and higher triglyceride levels. Patients infected with HCV should undergo T2DM screening and antidiabetic treatment. | Shira Yair-Sabag Elchanan Nussinson Ofir Ben-Assuli Fahmi Shibli Azmi Shahbari Shira Zelber-Sagi | 2016 | World Journal of Hepatology2016，8，30： | 1 |
| 7 | Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list显示文摘AIM: To characterize non-alcoholic fatty liver disease(NAFLD) presentation with esophageal varices. METHODS: We carried out a retrospective cohort study on 258 patients with esophageal varices at a single tertiary referral center. These patients underwent diagnosis of several liver diseases, including: NAFLDassociated cirrhosis, hepatitis B, hepatitis C, Wilson disease, autoimune liver diseases, and others. RESULTS: Of the 258 patients, 39% of patients exhibited esophageal varices due to NAFLD-associated cirrhosis. Of the 38(14.7%) patients developed hepatocellular carcinoma during follow-up, 52% were due to hepatitis B, 26% due to hepatitis C and 13.2% due to NAFLD. Of the 258 patients, 50.0% with NAFLD, 33.3% with hepatitis B, 26.3% with hepatitis C, and 58.3% with other diseases were alive at the end of the 5-year period with a significant difference according to the Kaplan-Meier log Rank test(P = 0.040). Portal vein thrombosis was detected in 47.5% of patients with NAFLD, in 29% of patients with hepatitis B, in 17% of patients with hepatitis C, and in 62% of patients with other related diseases(P < 0.0001). CONCLUSION: Our study showed a proportionally greater elevation in liver transplant candidacy in patients with NAFLD and portal vein thrombosis. Older patients were more prone to developing cirrhosis, hepatocellular carcinoma and a high mortality rate. However, younger patients exhibited more portal vein thrombosis and gastric varices. | Metin Basaranoglu Sonia M Najjar Ali Ebag Demirbag Hakan Senturk | 2016 | World Journal of Hepatology2016，8，7： | 1 |
| 8 | 恩格列净对乙型病毒性肝炎合并T2DM患者的疗效与安全性显示文摘目的:分析恩格列净在乙型病毒性肝炎合并2型糖尿病(T2DM)患者中应用疗效及其安全性。方法:选择在某医院就诊的42例乙型病毒性肝炎合并T2DM患者,随机平分为观察组和对照组。观察组给予恩格列净联合胰岛素降糖,对照组单纯使用胰岛素降糖,观察两组治疗效果及安全性。结果:治疗前,两组各项指标无明显差异(P>0.05)。治疗3 mon后,两组BMI、腰围、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、总胆固醇(TC)、甘油三酯(TG)等有明显差异(P<0.05),且观察组每日胰岛素用量明显低于对照组(P<0.05),但两组间谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清白蛋白(Alb)、总胆红素(TBiL)、乙肝病毒DNA定量(HBV-DNA)、肝脏纤维化指标等无明显差异(P>0.05)。治疗后,观察组BMI、腰围、FBC、HbA1c、FINS、HOMA-IR、TC、高密度胆固醇(HDL)均较治疗前明显改善(P<0.05),而ALT、AST、Alb、TBiL、HBV-DNA、肝脏纤维化指标等较治疗前无显著差异(P>0.05)。结论:恩格列净可明显改善乙型病毒性肝炎合并T2DM患者胰岛功能,减轻胰岛素抵抗,且不增加患者体重并有辅助降脂作用,但未观察到有改善肝纤维化的作用。恩格列净对此类患者是安全的,无严重不良反应发生。 | 张园园 李俊洁 吴丽娜 楚晓婧 刘爱萍 王崇贤 李俊 | 2022 | 河南大学学报(医学版)2022，41，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员